Protocols
C4THERAPEUTICS-CFT7455-1101 Phase I/II OPEN TO ACCRUAL
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
CHIMAGEN-CMG1A46-US01 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First in Human, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Triple-Specific T-Cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-Cell Hematologic Malignancies
IIT-ATALLAH-MCW-XEN21 Phase I OPEN TO ACCRUAL
MCW-XEN21: A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients with Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma
NURIX-NX-5948-301 Phase I OPEN TO ACCRUAL
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies